3:00 AM
Nov 07, 2018
 |  BC Extra  |  Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III trials in the indication. FMX103 is a topical 1.5% foam formulation of minocycline, a semisynthetic derivative of tetracycline.

The double-blind, U.S. FX2016-11 and FX2016-12 trials enrolled 751...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD